Trial Profile

Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% and <= 90% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning (IFM 2005-03).

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Antithymocyte globulin; Bortezomib; Busulfan; Ciclosporin; Fludarabine; Methotrexate
Indications Graft-versus-host disease; Multiple myeloma
Focus Therapeutic Use

15 Jan 2014 Biomarkers information updated
26 Jan 2011 Planned End Date (1 May 2015) added as reported by ClinicalTrials.gov.
26 Jan 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com